UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Holdings in Sotera Health Company $SHC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Sotera Health Company (NASDAQ:SHC) by 7.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 470,803 shares of the company’s stock after purchasing an additional 33,221 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Sotera Health were worth $8,357,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in SHC. CenterBook Partners LP boosted its position in shares of Sotera Health by 94.1% in the fourth quarter. CenterBook Partners LP now owns 151,529 shares of the company’s stock worth $2,673,000 after buying an additional 73,473 shares during the period. Militia Capital Management LLC acquired a new stake in shares of Sotera Health in the first quarter valued at about $3,877,000. Geode Capital Management LLC raised its holdings in shares of Sotera Health by 13.8% during the 4th quarter. Geode Capital Management LLC now owns 3,931,834 shares of the company’s stock valued at $69,372,000 after buying an additional 476,365 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Sotera Health by 13.4% during the 1st quarter. Bank of New York Mellon Corp now owns 1,403,971 shares of the company’s stock valued at $20,133,000 after buying an additional 166,055 shares during the period. Finally, Balefire LLC acquired a new position in Sotera Health during the 1st quarter worth approximately $1,476,000. 91.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Citigroup upped their price target on Sotera Health from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Wall Street Zen upgraded shares of Sotera Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 29th. The Goldman Sachs Group initiated coverage on shares of Sotera Health in a report on Friday, June 5th. They set a “buy” rating and a $20.00 price target for the company. Weiss Ratings raised shares of Sotera Health from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Finally, Barclays boosted their price objective on shares of Sotera Health from $19.00 to $22.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $21.50.

Sotera Health Price Performance

Shares of NASDAQ SHC opened at $18.90 on Tuesday. Sotera Health Company has a fifty-two week low of $13.09 and a fifty-two week high of $19.85. The business has a 50 day moving average price of $18.38 and a two-hundred day moving average price of $16.48. The company has a quick ratio of 2.55, a current ratio of 2.80 and a debt-to-equity ratio of 3.33. The firm has a market cap of $5.39 billion, a PE ratio of 33.16 and a beta of 1.77.

Sotera Health (NASDAQ:SHC) last announced its earnings results on Thursday, August 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.02. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%.The company had revenue of $321.38 million for the quarter, compared to analyst estimates of $309.70 million. During the same period in the prior year, the company posted $0.20 EPS. Sotera Health’s quarterly revenue was up 9.2% on a year-over-year basis. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. Sell-side analysts expect that Sotera Health Company will post 0.86 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Chairman Michael Petras, Jr. sold 850,000 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $18.50, for a total value of $15,725,000.00. Following the sale, the chairman directly owned 3,969,393 shares of the company’s stock, valued at $73,433,770.50. This represents a 17.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Michael Rutz sold 150,000 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $18.84, for a total transaction of $2,826,000.00. Following the transaction, the insider owned 334,279 shares in the company, valued at $6,297,816.36. This trade represents a 30.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 1,294,515 shares of company stock valued at $23,999,528. Insiders own 15.36% of the company’s stock.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.